Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry
Physicians treating patients with atrial fibrillation (AF) must weigh the benefits of anticoagulation in preventing stroke versus the risk of bleeding. Empirical models have been developed to predict such risks (CHADS 2 [congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and previous stroke or transient ischemic attack] score for stroke; ATRIA [Anticoagulation and Risk Factors in Atrial Fibrillation] score for bleeding), and we aimed to assess the degree to which these coincide with clinicians' estimates. Among 10 094 outpatients with AF in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry, agreement between physician-assessed stroke risk and CHADS 2 score was low. Similarly, agreement between physician-assessed bleeding risk and ATRIA score was also low. Physicians appeared to weigh different factors in their assessments of stroke and bleeding risk, and the use of anticoagulation was highest among patients with high stroke risk, by CHADS 2 score or physician assessment. In contrast, physician and empirical estimates of bleeding had limited impact on treatment choice. Overall treatment rates have been reported to be suboptimal, and these data may provide an explanation, in part. Although prospective studies have demonstrated the benefit of anticoagulation in patients stratified by CHADS 2 score, risk assessment at the patient level remains a challenge, for both stroke and bleeding, and such assignments have important implications for treatment decisions. See p 2005.
Transplantation-Free Survival and Interventions at 3 Years in the Single Ventricle Reconstruction Trial
In the Single Ventricle Reconstruction (SVR) trial, 1-year transplantation-free survival was better for the Norwood procedure with right ventricle-to-pulmonary artery shunt (RVPAS) compared with a modified Blalock-Taussig shunt. To address the longer-term outlook after the Norwood procedure with RVPAS versus a modified Blalock-Taussig shunt in a multicenter study, we compared the shunt groups with respect to a composite end point of death or transplantation, using all available follow-up, when the last enrolled patient had reached 3 years of age, pre-Fontan right ventricular ejection fraction, and unplanned interventions to 3 years of age. We found that by 3 years of age, transplantation-free survival no longer differed significantly between the shunt groups. The disproportionate number of later events in the RVPAS group eliminated its early survival advantage. The RVPAS group had slightly worse systemic right ventricular ejection fraction before the Fontan procedure. Furthermore, the hazard ratio for RVPAS versus a modified Blalock-Taussig shunt for catheter intervention increased over time: beyond 1 year after randomization, children assigned to RVPAS were more than twice as likely to have undergone a catheter intervention as those assigned to the modified Blalock-Taussig shunt group. These findings highlight the adverse longer-term effects of the RVPAS. Follow-up of the SVR cohort is underway to delineate the evolving natural history after the Norwood procedure using the RVPAS compared with the modified Blalock-Taussig shunt strategy. See p 2013.
Impact of Cardiac Resynchronization Therapy on Hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial
Cardiac resynchronization therapy (CRT) has been shown to reduce hospitalizations for heart failure (HF) in patients with mild to moderate HF. We report a detailed analysis of the causes of hospitalization, hospitalization rates, and hospitalization lengths of stay in patients randomized to implantable cardioverter-defibrillator (ICD) or ICD-CRT in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). At the 18-month follow-up, the proportion of patients hospitalized at least once for HF was significantly lower in the ICD-CRT group (11.3%) compared with the ICD group (15.6%; P=0.003). The proportions of patients hospitalized for a device-related indication were similar in the ICD-CRT group (16.4%) and ICD group (13.9%; P=0.148). The number of hospitalizations for any cause (n=1448 versus n=1553; P=0.042), any cardiovascular cause (n=667 versus n=790; P=0.017), and any HF cause (n=385 versus n=505; P<0.0001) was significantly lower in ICD-CRT group compared with the ICD group, whereas the number of hospitalizations for device-related causes was significantly higher in the ICD-CRT group compared with the ICD group (n=246 versus n=159; P<0.001). Although, the reduction in hospitalizations for HF in the CRT-ICD group was offset by an increased number of hospitalizations for device-related indications, the length of hospital stay for any cause was significantly lower in the ICD-CRT group (8.83±13.30 days) compared with the ICD group (9.59±14.40 days; P=0.005). The reduction in total number of hospitalizations and length of stay per hospitalization should translate into cost savings for healthcare systems, but this will require further analysis. See p 2021.
c-Cbl Inhibition Improves Cardiac Function and Survival in Response to Myocardial Ischemia
Myocardial infarction due to coronary artery occlusion is one of the leading causes of death worldwide. The loss of blood flow after myocardial infarction results in loss of cardiac myocytes in the ischemic zone, which diminishes cardiac contractility and impedes angiogenesis and repair. Although much is known about the pathways that promote the pathological remodeling responses, mechanisms that promote myocyte loss and impair cardiac function have not been as clearly defined. The ubiquitin proteasome system is largely responsible for the degradation of misfolded and damaged proteins as well as proteins involved in the control of components of Volume 129 ◼ Number 20 ◼ May 20, 2014
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May 20, 2014 the contractile apparatus and hypertrophic gene expression, thereby regulating cardiac hypertrophy and remodeling. In the present study, we show that expression of proto-oncogene Casitas b-lineage lymphoma (c-Cbl), an adaptor protein with an intrinsic E3 ubiquitin ligase activity that targets receptor and nonreceptor tyrosine kinases, is increased in human failing hearts. Inhibition of c-Cbl in mice reduces myocyte death, enhances angiogenesis, and improves cardiac function and survival in response to myocardial ischemia. Thus, modulating c-Cbl activation to attenuate myocyte death and to enhance angiogenesis may have potential implications in the treatment of cardiac disease. See p 2031.
Counseling African Americans to Control Hypertension: Cluster-Randomized Clinical Trial Main Effects
Blacks have the highest prevalence of hypertension in the United States, and they experience disproportionately higher rates of hypertension-related mortality compared with whites.
Although poor blood pressure (BP) control has been implicated as a potential mechanism for the racial disparities in cardiovascular outcomes, data are limited on the implementation of evidence-based multilevel interventions targeted at BP control in blacks. Counseling African Americans to Control Hypertension is the largest practice-based trial to evaluate the comparative effectiveness of a multicomponent intervention (provision of home BP monitoring, patient education, and lifestyle counseling to patients, as well as hypertension case rounds plus chart audits for physicians) versus the provision of print patient education and hypertension treatment guidelines, among 1059 hypertensive blacks (mean age, 56 years; 59% obese and 36% with diabetes mellitus) who receive care in community health centers. Although patients in both groups had significant BP reduction (-16 
Closing the Gap in Hypertension Control Between Younger and Older Adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010
Recent reports emphasize challenges in hypertension control and implicate the healthcare system generally and clinicians specifically for limited success. Although improvement in hypertension control is needed, progress in hypertension control appears to be underappreciated. From 1988 to 2010, blood pressure control to <140/<90 mm Hg in adults aged ≥60 years improved more than in younger adults as the age gap in control narrowed from 14% to 3%. In fact, nearly 70% of all older adults with hypertension attained an evidence-based blood pressure goal of <150/<90 mm Hg. Patients and their clinicians are to be commended for recognizing the benefits of better blood pressure control and taking action to initiate, intensify, and adhere to antihypertensive therapy, which underlies remarkable progress. The data suggest that ensuring that hypertensive patients have at least biannual healthcare visits and receive statins according to current guidelines could contribute to even better hypertension blood pressure control and fewer cardiovascular events in the years ahead. Further study to clarify the optimal systolic blood pressure goal for older adults could reduce uncertainty, leading to even better management and outcomes. See p 2052.
